Feliza Mirasol

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.

A predictive modeling approach can offer tighter process control, which can optimize bioreactor output.

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

The recent approvals of bispecific antibodies have opened the gate for the further development of these complex molecules.

Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure.

One can use modeling methods to generate data and shorten development timelines in preclinical studies.

Having a clear clinical strategy early on can shave time off overall development projects.